| Missy Griffith Carter, PA-C | |
|
4311 11th Ave Ne Ste 200, Seattle, WA 98105-6367 | |
| (206) 616-4001 | |
| Not Available |
| Full Name | Missy Griffith Carter |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 7 Years |
| Location | 4311 11th Ave Ne Ste 200, Seattle, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689184392 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | PA60796670 (Washington) | Secondary |
| 363A00000X | Physician Assistant | PA60796670 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Medical Center | Tacoma, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Franciscan Medical Group | 0547173866 | 1115 |
News Archive
Syngenta announced today that it plans to construct a new state-of-the-art biotechnology research facility adjacent to its existing research campus in Research Triangle Park, North Carolina. The $71 million investment, which is scheduled to begin in June 2011, will focus on discovering and developing new agronomic traits to bring innovative solutions to growers across the world.
Transcatheter aortic valve replacement is a revolutionary technology for the treatment of patients with severe calcific aortic stenosis.
An age group analysis of data from the ADvance trial has shown that participants over the age of 65 continue to derive the most benefit from Deep Brain Stimulation of the fornix, as observed in the data from the phase 2 findings (12 - 24 months) of the Phase II trial.
A new study from Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia, who are members of the Southwest Oncology Group (SWOG), suggests that certain changes in prostate-specific antigen (PSA) levels may serve as surrogate endpoints for prostate cancer survival.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Missy Griffith Carter, PA-C 5123 N 39th St, Tacoma, WA 98407-3623 Ph: (206) 300-0828 | Missy Griffith Carter, PA-C 4311 11th Ave Ne Ste 200, Seattle, WA 98105-6367 Ph: (206) 616-4001 |
News Archive
Syngenta announced today that it plans to construct a new state-of-the-art biotechnology research facility adjacent to its existing research campus in Research Triangle Park, North Carolina. The $71 million investment, which is scheduled to begin in June 2011, will focus on discovering and developing new agronomic traits to bring innovative solutions to growers across the world.
Transcatheter aortic valve replacement is a revolutionary technology for the treatment of patients with severe calcific aortic stenosis.
An age group analysis of data from the ADvance trial has shown that participants over the age of 65 continue to derive the most benefit from Deep Brain Stimulation of the fornix, as observed in the data from the phase 2 findings (12 - 24 months) of the Phase II trial.
A new study from Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia, who are members of the Southwest Oncology Group (SWOG), suggests that certain changes in prostate-specific antigen (PSA) levels may serve as surrogate endpoints for prostate cancer survival.
› Verified 6 days ago